Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

H.C. Wainwright has recently reiterated Microbot Medical Inc (MBOT) stock to Buy rating, as announced on January 13, 2020, according to Finviz. Earlier, on December 24, 2019, H.C. Wainwright had ...

H.C. Wainwright reiterated its Buy rating and $27.00 price target for CleanSpark Inc. (NASDAQ:CLSK) shares, representing ...

Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio forecasts that the company ...

Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for Genmab A/S in a report issued on ...

H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Hold rating on Agenus (AGEN – Research Report). The company’s shares ...

H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...

Greetings, and welcome to LSI Industries Fiscal 2025 Second Quarter Results Conference Call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the ...

On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88. The firm's ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...